ASCO 2023 | The benefits of 177Lu-PSMA-617 plus olaparib for prostate cancer

Shahneen Sandhu, MBBS, FRACP, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the results of the Phase I LuPARP study (NCT03874884), which tested a fixed dose of 177Lu-PSMA-617, alongside nine different doses of olaparib. Treatment combinations were escalated and a dose was defined from day minus 4-18, at 300mg twice a day, along with 7.4 GBq of 177Lu-PSMA-617, every 6 weeks intravenously. This combination was found to be tolerable and prostate-specific antigen (PSA) responses were stronger than in studies investigating 177Lu-PSMA-617 monotherapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.